Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ALX Oncology
Biotech
ALX links CD47 drug to improved response rate in solid tumors
ALX Oncology sees a future for its beleaguered anti-CD47 drug in solid tumors. The biotech reported a 52% response rate in recipients of the therapy.
Nick Paul Taylor
Oct 3, 2023 6:15am
Illumina nets new CEO—Chutes & Ladders
Sep 8, 2023 9:30am
ALX follows Gilead in axing cancer trials as data disappoint
Aug 11, 2023 9:05am
After fast-tracking ALX's cancer hopeful, FDA pumps the brakes
Dec 7, 2020 9:35am
2 early-stage biotechs gun for $175M as IPO waters remain warm
Jun 29, 2020 7:20am
After $105M funding round, ALX Oncology nabs FDA fast-track tag
Feb 18, 2020 8:01am